Table 1.
Baseline characteristics of population diagnosed with MetS according to different definitions
| Characteristic | AHA/NHLBI | IDF | EGIR | Total population |
|---|---|---|---|---|
| Participants having MetS (n, %) | 3055 (35.3) | 3646 (42.2) | 1680 (19.4) | 8643 |
| Age, years | 64.2 (58.8–72.5)* | 64.0 (58.8–72.6)* | 62.1 (57.1–70.8) | 62.7 (57.6–71.2) |
| Female sex (n, %) | 1790 (58.6) | 2090 (57.3) | 919 (54.7)* | 4983 (57.7) |
| Body mass index (kg/m2) | 29.3 ± 4.1* | 28.9 ± 3.9* | 30.3 ± 4.3* | 27.0 ± 4.1 |
| Waist-circumference, cm | 100.0 ± 10.8* | 98.9 ± 10.5* | 102.0 ± 11.2* | 92.8 ± 11.8 |
| Systolic blood pressure, mmHg | 145.6 ± 19.0* | 145.3 ± 19.1* | 144.1 ± 18.9* | 138.3 ± 20.8 |
| Diastolic blood pressure, mmHg | 81.4 ± 11.4* | 81.3 ± 11.4* | 82.6 ± 11.7* | 78.8 ± 11.4 |
| Total cholesterol, mmol/l | 5.8 ± 1.1* | 5.8 ± 1.1* | 5.7 ± 1.1 | 5.8 ± 1.0 |
| HDL cholesterol, mmol/l | 1.2 (1.0–1.4)* | 1.2 (1.0–1.4)* | 1.2 (1.0–1.4)* | 1.4 (1.1–1.7) |
| Triglycerides, mmol/l | 1.8 (1.4–2.3)* | 1.7 (1.3–2.2)* | 1.8 (1.3–2.4)* | 1.3 (1.0–1.8) |
| Insulin, pmol/L | 92 (67–129)* | 88 (64–123)* | 131 (111–166)* | 69 (49–97) |
| Glucose, mg/L | 5.8 (5.4–6.1)* | 5.7 (4.5–6.1)* | 5.8 (5.4–6.2)* | 5.4 (1.1–1.7) |
| CRP, mg/mL | 2.2 (1.0–4.4)* | 2.0 (0.9–4.1)* | 2.2 (1.0–4.6)* | 1.5 (0.6–3.3) |
| Hypertension treatment (n, %) | 1045 (34.2)* | 1197 (32.8)* | 92 (41.2)* | 1873 (21.7) |
| Antidiabetic treatment (n, %) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Lipid treatment (n, %) | 563 (18.4)* | 630 (17.3)* | 353 (21.0)* | 1255 (14.5) |
| Current smoking (n, %) | 287 (9.4) | 329 (9.0)* | 114 (6.8)* | 813 (9.4) |
| Caucasian descent (n, %) | 2732 (98.2) | 3255 (98.1) | 1482 (96.9) | 7655 (97.8) |
| Prevalent type 2 diabetes (n, %) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0 %) |
| Prevalent CHD (n, %) | 218 (7.1)* | 249 (6.8)* | 121 (7.2)* | 518 (6.0) |
| Prevalent Stroke (n, %) | 95 (3.1)* | 107 (3.0)* | 54 (3.2)* | 196 (2.3) |
Continuous data are mean ± SD when normally distributed. Otherwise median with interquartile range
AHA/NHLBI, American heart association/national heart, lung, and blood institute; IDF, International Diabetes Federation; EGIR, European Group for the Study of Insulin Resistance; MetS, metabolic syndrome; HDL, high-density lipoprotein; CRP, C-reactive protein; CHD, coronary heart disease
* Significant difference between MetS and non-MetS after correction for age and sex (P < 0.05)